Lincoln Pharmaceuticals has set aside a sum of Rs 30 crore for the expansion of its Cephalosporin product portfolio and will soon launch them in India.

The company, in a regulatory filing also announced that it has acquired a facility in Mehsana for the expansion and expects the commercial operations from the plant to start from March 2022 and expects approximately Rs 150 crore sales over the next three years from the new facility.

The plant will cater to all the Cephalosporin products such as tablets, capsules, dry syrup and injectables. The company is planning to start product registration soon for the domestic and export markets, it added.

"The entire expansion for Cephalosporin products will be funded from internal accruals. The company has earmarked a total investment of around Rs 30 crore for this expansion," Lincoln Pharmaceuticals MD Mahendra Patel said.

The company plans to manufacture 20 plus Cephalosporin products including cefalexin oral suspension BP, clavulanate tablets, cefixime capsules, cefuroxime axetil tablets among others, the filing said.

The acquired facility in Mehsana, Gujarat has been designed as per the PIC's and European Region. The company is in the process of applying for WHO GMP Certifications for the facility and expects to receive the same by December 2021.

It plans to export the products to Africa, Latin America and Southeast Asia markets, it added.

"Cephalosporin is a bactericidal, broad-spectrum, and P-lactam antibiotic originally derived from fungus Acremonium, which is used to treat bacterial infections such as pneumonia, skin infections, ear infection, strep throat, staph infections, tonsillitis, bronchitis among others," the filing said.